ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$5.79 USD
-0.19 (-3.18%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $5.80 +0.01 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IBRX 5.79 -0.19(-3.18%)
Will IBRX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IBRX
ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock Now
IBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden Cross
Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
Other News for IBRX
3 Top Cancer Treatment Stocks to Buy Now
Largest borrow rate increases among liquid names
ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
ImmunityBio spikes after commercial update on lead drug Anktiva